<DOC>
	<DOCNO>NCT02598505</DOCNO>
	<brief_summary>The purpose study : 1 . To confirm safety Indacaterol stable Heart Failure . 2 . To determine whether beta 2 alveolar receptor stimulation Indacaterol able ameliorate lung diffusion heart Failure patient treat beta blocker . 3 . To compare effect Indacaterol patient treat non-selective beta blocker ( Carvedilol ) beta 1-selective beta blocker ( Bisoprolol ) .</brief_summary>
	<brief_title>Indacaterol Heart Failure Patients : Any Role Lung Fluid Regulation</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Male female adult age â‰¥ 18 year sign Informed Consent Form . Patients light chronic obstructive pulmonary disease never treat bronchodilator drug Cooperative patient Patients clinical diagnosis chronic heart failure ( HF ) chronic myeloproliferative disorder ejection fraction &lt; 40 % B Blockers therapy since least 2 month . Optimized individually tailored drug treatment include B blocker ( Carvedilol bisoprolol ) Capability perform Cardiopulmonary Exercise Test lung diffusion test History clinical documentation : pulmonary embolism primary valvular heart disease pericardial disease severe obstructive lung disease significant peripheral vascular disease exerciseinduced angina , st change , severe arrhythmia . Patients diabetes Type I uncontrolled diabetes Type II include patient history blood glucose level consistently outside normal range HbA1c &gt; 8.0 % total hemoglobin measure . Use bronchodilator . Patients history ( family history ) long QT syndrome whose corrected QT interval interval ( Fridericia ) measure Visit 2 prolong : &gt; 450 m ( male ) &gt; 470 m ( female ) assess central ECG interpretation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>